OS Therapies Incorporated has reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $6.9 million for the third quarter, compared to a loss of $2.9 million in the same period last year. For the nine months ended September 30, 2025, the net loss totaled approximately $15.3 million, up from $5.9 million in the prior year. The increase in losses is attributed to heightened research and development expenses, which surged to $7.6 million for the nine-month period, compared to $2.0 million in 2024, primarily due to costs associated with the ongoing Phase IIb clinical trial for its lead product candidate, OST-HER2.
In terms of operational metrics, OS Therapies has made notable strides in its clinical development. The company is currently focused on the commercialization of treatments for Osteosarcoma, with OST-HER2 showing promising results in clinical trials. The company announced that 75% of patients treated with OST-HER2 achieved two-year overall survival, significantly higher than the historical control rate of 40%. This data is expected to support regulatory submissions to the FDA and other agencies in the coming months.
Strategically, OS Therapies has expanded its operations through the acquisition of the HER2 Assets from Ayala Pharmaceuticals, which includes two investigational new drug filings. The total purchase price for these assets was $8 million, consisting of cash and stock. This acquisition is expected to enhance the company's product pipeline and facilitate further research into additional solid tumors. Additionally, the company has formed two wholly-owned subsidiaries, OS Animal Health Corp and OS Therapies UK LTD, to broaden its operational scope and research capabilities.
Financially, OS Therapies has seen a decrease in cash reserves, with cash on hand reported at $1.9 million as of September 30, 2025, down from $5.5 million at the end of 2024. The company has funded its operations primarily through the sale of convertible notes and equity securities, raising approximately $41.1 million to date. The company anticipates needing additional capital to sustain operations and is exploring various financing options, including public and private equity offerings.
Looking ahead, OS Therapies aims to submit a conditional Marketing Authorization Application to the UK Medicines and Healthcare products Regulatory Agency in December 2025 and a Biologics License Application to the FDA in January 2026. The company is optimistic about the potential for regulatory approval and plans to leverage its clinical data to expand the use of OST-HER2 in treating other solid tumors. However, the company acknowledges the ongoing need for capital to support its ambitious development plans and operational needs.
About OS Therapies Inc
OS Therapies Inc. is a biopharmaceutical company developing innovative immunotherapies and targeted treatments for osteosarcoma and other solid tumors. Its pipeline includes OST-HER2, an immunotherapy for rare cancers, and OST-tADC, a tunable antibody-drug conjugate platform targeting multiple cancers. The company focuses on clinical-stage development, leveraging proprietary technology, strategic collaborations, and regulatory designations to address unmet medical needs in oncology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.